GPT and hepatocellular carcinoma: Specifically, the detailed adverse reactions of the combination treatment were fatigue, nausea and vomiting, diarrhea, hand-foot syndrome, rash, AST/ALT elevation, and proteinuria (incidence of >20%), which were in concert with the safety profile of exploratory trial regarding apatinib plus camrelizumab in patients with advanced hepatocellular carcinoma [36].